HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AB&B BIO-TECH-B

29.320

0.000

Volume:- -

Turnover:- -

Market Cap:11.52B

PE:-34.87

High:29.320

Open:29.320

Low:29.320

Close:29.320

52wk High:73.000

52wk Low:28.880

Shares:393.00M

HK Float Shares:296.36M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.841

ROE:--

ROA:--

PB:292.63

PE(LYR):-34.87

PS:30.42

Loading ...

Overview Company News Filings

AB&B BIO-TECH-B (02627) Commences Phase I/II Trials for Its Adjuvanted RSV Vaccine

AB&B Bio-Tech wins China NMPA approval for RSV vaccine clinical trial program

AB&B Bio-Tech starts Phase I/II trials for self-developed recombinant RSV vaccine candidate

Ab&B Bio-Tech obtains China CDE IND approval for mRNA RSV vaccine candidate

Bulletin Express

AB&B BIO-TECH-B Receives Chinese Regulatory Nod for mRNA RSV Vaccine Clinical Trial Application

AB&B Bio-Tech wins China CDE IND approval for self-developed mRNA RSV vaccine

Ab&B Bio Tech Co Ltd Js - China Cde Approves Ind Application for Ab+B Bio-Tech's Mrna Rsv Vaccine Candidate

THOMSON REUTERS

Ab&B Bio-Tech Calls 27 May 2026 EGM; Plans to Abolish Supervisory Committee, Revamp Governance and Appoint New INED & Auditor

Bulletin Express

AB&B Bio-Tech announces 2026 extraordinary general meeting

AB&B BIO-TECH-B Receives Stock Exchange Resumption Guidance, Trading Halt Continues

AB&B Bio-Tech auditor resignation delays annual results, shares remain suspended in Hong Kong

AB&B BIO-TECH-B Appoints Pak Shun as New Auditor

Ab&B Bio-Tech Nominates Ms. Lui Mei Ka as Independent Director, Plans Audit Committee Adjustment and Charter Revision

Bulletin Express

AB&B BIO-TECH-B Nominates Leimeijia as Independent Non-Executive Director Candidate

AB&B BIO-TECH-B Appoints Pak Chun as New Auditor

AB&B Bio-Tech nominates Lui Mei Ka as independent non-executive director candidate

AB&B Bio-Tech Proposes Prism Hong Kong as Successor Auditor; 2025 Audit Targeted for Completion by May 2026

Bulletin Express

AB&B Bio-Tech names Prism Hong Kong as new auditor after Deloitte resignation

AB&B BIO-TECH-B Announces Changes to Strategy Committee Composition

AB&B Bio-Tech files list of directors with Hong Kong Stock Exchange

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/02627/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"AB&B BIO-TECH-B","latestPrice":29.32,"timestamp":1790904038145,"preClose":29.32,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":296361845,"shares":393000000,"eps":-0.8407476805822578,"marketStatus":"Halted","change":0,"latestTime":"10-02 09:20:38","open":29.32,"high":29.32,"low":29.32,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.7311815827676855,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":5,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":29.32,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.840748,"shares":393000000,"dividePrice":0,"high":29.32,"amplitude":0,"preClose":29.32,"low":29.32,"week52Low":28.88,"pbRate":"292.63","psRate":"30.42","week52High":73,"institutionHeld":0,"latestPrice":29.32,"eps":-0.8407476805822578,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.7311815827676855,"open":29.32,"prevYearClose":40.24,"prevWeekClose":29.32,"prevMonthClose":29.32,"prevQuarterClose":29.32,"fiveDayClose":29.32,"twentyDayClose":29.32,"sixtyDayClose":29.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2026-03-31","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774920600000,"name":null,"time":"","dateTimestamp":1774886400000,"actualEps":null},{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2026-09-30","current":-40.099478,"percent":0.978648,"low":-109.844469,"twenty":-72.652646,"median":-60.908613,"eighty":-44.393395,"high":-18.07815,"avg":-58.401708,"sd":14.601788,"marketCap":11535737032},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-12","current":-62.655098,"twenty":-66.251138,"median":-63.08644,"eighty":-59.27469,"marketCap":19380982476},{"date":"2025-09-19","current":-81.048551,"twenty":-68.315951,"median":-63.912829,"eighty":-59.882299,"marketCap":19888523430},{"date":"2025-09-26","current":-77.095946,"twenty":-77.153546,"median":-65.395346,"eighty":-60.155426,"marketCap":18869507096},{"date":"2025-10-03","current":-76.784092,"twenty":-77.86406,"median":-66.074095,"eighty":-61.128611,"marketCap":18838031688},{"date":"2025-10-10","current":-75.450727,"twenty":-78.338288,"median":-66.623148,"eighty":-61.710077,"marketCap":18483933348},{"date":"2025-10-17","current":-70.044793,"twenty":-77.841467,"median":-68.315951,"eighty":-62.332762,"marketCap":17146228508},{"date":"2025-10-24","current":-70.694139,"twenty":-77.356453,"median":-69.86748,"eighty":-62.632094,"marketCap":17311474400},{"date":"2025-10-31","current":-64.652972,"twenty":-77.130506,"median":-68.586563,"eighty":-62.679826,"marketCap":15855736780},{"date":"2025-11-07","current":-65.014442,"twenty":-77.0495,"median":-67.012733,"eighty":-63.012535,"marketCap":15934425300},{"date":"2025-11-14","current":-69.152784,"twenty":-76.901535,"median":-66.692171,"eighty":-63.572329,"marketCap":16996720320},{"date":"2025-11-21","current":-64.47659,"twenty":-76.671062,"median":-66.251138,"eighty":-63.813259,"marketCap":15839999076},{"date":"2025-11-28","current":-66.221916,"twenty":-76.081201,"median":-65.883561,"eighty":-63.948664,"marketCap":16327867900},{"date":"2025-12-05","current":-64.387851,"twenty":-75.140133,"median":-65.711289,"eighty":-64.052768,"marketCap":15902949892},{"date":"2025-12-12","current":-65.09579,"twenty":-74.230454,"median":-65.51992,"eighty":-64.060512,"marketCap":16107540044},{"date":"2025-12-19","current":-64.75238,"twenty":-73.314016,"median":-65.09579,"eighty":-64.128623,"marketCap":16060326932},{"date":"2025-12-24","current":-63.88714,"twenty":-72.937878,"median":-65.019631,"eighty":-64.128296,"marketCap":15895081040},{"date":"2026-01-02","current":-63.38466,"twenty":-72.68164,"median":-64.955716,"eighty":-63.907691,"marketCap":15832130224},{"date":"2026-01-09","current":-64.42138,"twenty":-72.421694,"median":-64.920623,"eighty":-63.984499,"marketCap":16131146600},{"date":"2026-01-16","current":-79.012958,"twenty":-72.68164,"median":-65.002626,"eighty":-63.984499,"marketCap":19849179170},{"date":"2026-01-23","current":-80.264585,"twenty":-74.684429,"median":-65.09579,"eighty":-64.012742,"marketCap":20144261120},{"date":"2026-01-30","current":-75.685884,"twenty":-76.499114,"median":-65.441715,"eighty":-64.034272,"marketCap":19081966100},{"date":"2026-02-06","current":-72.661412,"twenty":-75.84841,"median":-65.678772,"eighty":-64.110439,"marketCap":18365900568},{"date":"2026-02-13","current":-79.706332,"twenty":-76.558032,"median":-65.817553,"eighty":-64.12895,"marketCap":20262293900},{"date":"2026-02-20","current":-82.611175,"twenty":-76.790716,"median":-65.857422,"eighty":-64.132361,"marketCap":20970490580},{"date":"2026-02-27","current":-82.941496,"twenty":-77.55936,"median":-66.221916,"eighty":-64.146544,"marketCap":21285244660},{"date":"2026-03-06","current":-81.374491,"twenty":-78.249638,"median":-66.33369,"eighty":-64.163416,"marketCap":20714752890},{"date":"2026-03-13","current":-88.155391,"twenty":-78.824484,"median":-66.830053,"eighty":-64.221195,"marketCap":22544260980},{"date":"2026-03-20","current":-60.352659,"twenty":-78.705126,"median":-66.485266,"eighty":-64.132361,"marketCap":15375736808},{"date":"2026-03-27","current":-47.779776,"twenty":-78.691316,"median":-66.244034,"eighty":-64.004997,"marketCap":12141638636},{"date":"2026-04-02","current":-45.178314,"twenty":-78.677046,"median":-65.897052,"eighty":-63.746879,"marketCap":11535737032},{"date":"2026-04-10","current":-44.832534,"twenty":-78.441179,"median":-65.857422,"eighty":-63.430885,"marketCap":11535737032},{"date":"2026-04-17","current":-44.813717,"twenty":-78.181043,"median":-65.711289,"eighty":-63.227242,"marketCap":11535737032},{"date":"2026-04-24","current":-44.811176,"twenty":-78.060991,"median":-65.51992,"eighty":-62.332762,"marketCap":11535737032},{"date":"2026-04-30","current":-44.783221,"twenty":-78.021843,"median":-65.28076,"eighty":-60.389723,"marketCap":11535737032},{"date":"2026-05-08","current":-44.644729,"twenty":-77.873074,"median":-65.02482,"eighty":-59.352088,"marketCap":11535737032},{"date":"2026-05-15","current":-44.527613,"twenty":-77.457906,"median":-64.955716,"eighty":-54.162029,"marketCap":11535737032},{"date":"2026-05-22","current":-44.62961,"twenty":-77.130506,"median":-64.865742,"eighty":-48.015114,"marketCap":11535737032},{"date":"2026-05-29","current":-44.474957,"twenty":-77.072723,"median":-64.7737,"eighty":-45.186782,"marketCap":11535737032},{"date":"2026-06-05","current":-44.410504,"twenty":-76.942339,"median":-64.709555,"eighty":-44.836445,"marketCap":11535737032},{"date":"2026-06-12","current":-44.440563,"twenty":-76.790716,"median":-64.652972,"eighty":-44.816847,"marketCap":11535737032},{"date":"2026-06-18","current":-44.334195,"twenty":-76.784092,"median":-64.606806,"eighty":-44.811176,"marketCap":11535737032},{"date":"2026-06-26","current":-44.551763,"twenty":-76.501517,"median":-64.559082,"eighty":-44.783221,"marketCap":11535737032},{"date":"2026-07-03","current":-44.518459,"twenty":-76.499114,"median":-64.484566,"eighty":-44.746029,"marketCap":11535737032},{"date":"2026-07-10","current":-44.573161,"twenty":-76.047687,"median":-64.42138,"eighty":-44.683785,"marketCap":11535737032},{"date":"2026-07-17","current":-44.415099,"twenty":-75.735703,"median":-64.384175,"eighty":-44.631174,"marketCap":11535737032},{"date":"2026-07-24","current":-44.405121,"twenty":-75.569622,"median":-64.258799,"eighty":-44.611538,"marketCap":11535737032},{"date":"2026-07-31","current":-44.320924,"twenty":-75.486659,"median":-64.151322,"eighty":-44.575108,"marketCap":11535737032},{"date":"2026-08-07","current":-44.235034,"twenty":-75.015399,"median":-64.128705,"eighty":-44.551763,"marketCap":11535737032},{"date":"2026-08-14","current":-44.179104,"twenty":-74.694617,"median":-64.015323,"eighty":-44.527613,"marketCap":11535737032},{"date":"2026-08-21","current":-44.081684,"twenty":-74.600848,"median":-63.899985,"eighty":-44.518459,"marketCap":11535737032},{"date":"2026-08-28","current":-44.071692,"twenty":-73.959632,"median":-63.62737,"eighty":-44.474957,"marketCap":11535737032},{"date":"2026-09-04","current":-44.054007,"twenty":-73.51655,"median":-63.388964,"eighty":-44.44038,"marketCap":11535737032},{"date":"2026-09-11","current":-43.994636,"twenty":-73.298392,"median":-63.28808,"eighty":-44.416196,"marketCap":11535737032},{"date":"2026-09-18","current":-43.937227,"twenty":-73.032481,"median":-62.686008,"eighty":-44.409254,"marketCap":11535737032},{"date":"2026-09-25","current":-44.021126,"twenty":-72.771998,"median":-61.935524,"eighty":-44.401333,"marketCap":11535737032},{"date":"2026-09-30","current":-43.939152,"twenty":-72.652646,"median":-60.908613,"eighty":-44.393395,"marketCap":11535737032}],"updateTime":1790937799074},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1112879198","title":"AB&B BIO-TECH-B (02627) Commences Phase I/II Trials for Its Adjuvanted RSV Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1112879198","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112879198?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:48","pubTimestamp":1778676509,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the group has recently initiated Phase I and Phase II clinical trials for its self-developed adjuvanted recombinant Respiratory Syncytial Virus (RSV) vaccine...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159646","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635822907","title":"AB&B Bio-Tech wins China NMPA approval for RSV vaccine clinical trial program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635822907","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635822907?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:41","pubTimestamp":1778676088,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech said China NMPA granted clinical trial authorization in August 2025 for its adjuvanted recombinant RSV vaccine made in CHO cells.Phase I and Phase II trials have been initiated.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL9bpbcH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782216","title":"AB&B Bio-Tech starts Phase I/II trials for self-developed recombinant RSV vaccine candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782216?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:41","pubTimestamp":1778676086,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech launched Phase I and Phase II clinical trials for its self-developed recombinant RSV vaccine using CHO cells with an adjuvant.No clinical results have been presented; trials have just started following China IND clearance received in August 2025.Preclinical work indicated stronger immune response, improved stability, and a safety profile supportive of advancing into human testing, without reporting clinical outcomes.Program positions company in RSV prevention market where limited treatment options keep vaccination central to disease control strategy.H-share trading remains suspended from April 1, 2026 pending further notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6jLvPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192053390","title":"Ab&B Bio-Tech obtains China CDE IND approval for mRNA RSV vaccine candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1192053390","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192053390?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:03","pubTimestamp":1778245399,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (Ab&B Bio-Tech) announced that China’s Center for Drug Evaluation (CDE) has cleared the Investigational New Drug (IND) application for the Group’s self-developed messenger...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183165347","title":"AB&B BIO-TECH-B Receives Chinese Regulatory Nod for mRNA RSV Vaccine Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1183165347","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183165347?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245219,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that, following the U.S. Food and Drug Administration's approval of its Investigational New Drug (IND) application in the United States on November 7, 2025, the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","159646","IND","BK4532","BK4533","BK4548","BK4585","02627","MRNA","BK4588","MRNX","MRNY","BK4534","BK4568","BK4551","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459787","title":"AB&B Bio-Tech wins China CDE IND approval for self-developed mRNA RSV vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459787","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459787?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:56","pubTimestamp":1778244989,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech secured China CDE clearance for an investigational new drug filing for its self-developed mRNA RSV vaccine candidate.U.S. FDA had cleared the vaccine’s IND on Nov. 7, 2025.H-share trading remains suspended in Hong Kong since April 1, 2026, pending further notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL1wWb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459246","title":"Ab&B Bio Tech Co Ltd Js - China Cde Approves Ind Application for Ab+B Bio-Tech's Mrna Rsv Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459246?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:56","pubTimestamp":1778244960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141249357","title":"Ab&B Bio-Tech Calls 27 May 2026 EGM; Plans to Abolish Supervisory Committee, Revamp Governance and Appoint New INED & Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=1141249357","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141249357?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:22","pubTimestamp":1778192560,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS has issued a circular convening an Extraordinary General Meeting (EGM) for 10:00 a.m. (Hong Kong time) on 27 May 2026 at No. 32 Xinglin Road, Medical High-tech Zone,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126730","title":"AB&B Bio-Tech announces 2026 extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126730","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633126730?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:56","pubTimestamp":1778165774,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech will hold an extraordinary general meeting in Taizhou, Jiangsu, on May 27, 2026.Shareholders will vote on scrapping supervisory committee, followed by amendments to articles of association.Meeting will also consider changes to internal corporate governance policies, appointment of an independent non-executive director, appointment of Prism as auditor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLb6Dv3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142399380","title":"AB&B BIO-TECH-B Receives Stock Exchange Resumption Guidance, Trading Halt Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=1142399380","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142399380?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:17","pubTimestamp":1777457853,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that on April 24, 2026, the company received a letter from the Stock Exchange outlining the following guidance for resuming trading of its shares: (i) Conduct an...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631996575","title":"AB&B Bio-Tech auditor resignation delays annual results, shares remain suspended in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2631996575","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631996575?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:00","pubTimestamp":1777456816,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech shares remain suspended in Hong Kong since April 1, 2026 due to delayed publication of fiscal 2025 annual results.Stock Exchange issued resumption conditions that include publishing all outstanding financial results required under Listing Rules.Company must address any audit modifications as part of resumption process.HKEX warned listing may be cancelled if trading does not resume by Sept. 30, 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4h8qN1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148727676","title":"AB&B BIO-TECH-B Appoints Pak Shun as New Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=1148727676","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148727676?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:30","pubTimestamp":1777249845,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has announced that, following the resignation of Deloitte Touche Tohmatsu and the resulting vacancy in the company's auditor position, the Board of Directors has resolved,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105109040","title":"Ab&B Bio-Tech Nominates Ms. Lui Mei Ka as Independent Director, Plans Audit Committee Adjustment and Charter Revision","url":"https://stock-news.laohu8.com/highlight/detail?id=1105109040","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105109040?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:43","pubTimestamp":1777041806,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS has proposed three board-level changes aimed at strengthening governance and internal controls. The Board has nominated Ms. Lui Mei Ka, aged 38, to serve as an independent...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169293447","title":"AB&B BIO-TECH-B Nominates Leimeijia as Independent Non-Executive Director Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1169293447","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169293447?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:38","pubTimestamp":1777041517,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has announced a proposal from its board of directors. The board has recommended the nomination of Ms. Leimeijia as a candidate for independent non-executive director for the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160023017","title":"AB&B BIO-TECH-B Appoints Pak Chun as New Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=1160023017","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160023017?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:32","pubTimestamp":1777041134,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has announced that following the resignation of Deloitte Touche Tohmatsu, the position of the company's auditor became vacant. The board of directors has resolved, upon the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629984096","title":"AB&B Bio-Tech nominates Lui Mei Ka as independent non-executive director candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2629984096","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629984096?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:25","pubTimestamp":1777040706,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech nominated Lui Mei Ka as independent non-executive director, pending shareholder vote.Lui is managing director at Merit Corporate Services, previously served as CFO and company secretary at GR Life Style.Audit Committee lineup set to change, with Lui slated to join once elected.Articles of association amendments would shift board structure to at least three independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDLb0MjG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161","BK1229","BK1258","00108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116430595","title":"AB&B Bio-Tech Proposes Prism Hong Kong as Successor Auditor; 2025 Audit Targeted for Completion by May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1116430595","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116430595?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:23","pubTimestamp":1777040588,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech CO., LTD. JS announced a plan to appoint Prism Hong Kong Limited as its new external auditor, filling the vacancy created by the recent resignation of Deloitte Touche Tohmatsu. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840837","title":"AB&B Bio-Tech names Prism Hong Kong as new auditor after Deloitte resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840837","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629840837?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:17","pubTimestamp":1777040249,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech proposed appointing Prism Hong Kong as auditor to fill vacancy left by Deloitte Touche Tohmatsu resignation.Appointment takes effect once shareholders approve it at a general meeting.Prism forecast completion of fiscal 2025 audit by end-May 2026.Proposed audit fee set at RMB 2.4 million.H-share trading remains suspended since April 1, 2026 amid delayed 2025 annual results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL5lb7Xh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190169040","title":"AB&B BIO-TECH-B Announces Changes to Strategy Committee Composition","url":"https://stock-news.laohu8.com/highlight/detail?id=1190169040","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190169040?lang=en_us&edition=fundamental","pubTime":"2026-04-19 19:40","pubTimestamp":1776598814,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has announced that its board of directors has reviewed and approved an adjustment to the membership of the board's strategy committee. The changes are effective from the date...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628764655","title":"AB&B Bio-Tech files list of directors with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2628764655","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628764655?lang=en_us&edition=fundamental","pubTime":"2026-04-19 19:36","pubTimestamp":1776598616,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech  filed updated list of directors with Hong Kong Stock Exchange dated April 19, 2026.An Youcai listed as executive director, serving as chairman of board.Board comprised three executive directors, three non-executive directors, three independent non-executive directors.Committee leadership set out for four board committees, including Audit Committee chaired by Li Jianjun.Remuneration and Appraisal Committee chaired by Chen Chengbei, Nomination Committee chaired by Li Xiangming.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 19, 2026, and is so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL3WrttZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}